January 3rd 2024
This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.
Perspectives on intravenous bevacizumab repackaged for intravitreal use
June 15th 2022Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
Key discovery: Humanin G reduces protein levels of inflammation markers associated with AMD
June 8th 2022According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.
Outlook Therapeutics submits BLA for ophthalmic bevacizumab ONS-5010 as treatment for wet AMD
March 31st 2022If the Biologics License Application is approved by the FDA, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.
Phase 2b/3 results for nAMD candidate KSI-301 revealed by Kodiak Sciences
February 27th 2022KSI-301, a therapy for patients with nAMD, did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks; however, it was safe and well-tolerated with no new or unexpected safety signals.
BREAKING NEWS: FDA approves faricimab for treatment of wet AMD, DME
January 29th 2022Genentech’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.
Faricimab improved and maintained vision for patients with wet AMD, DME
January 26th 2022Across four studies, about half of eligible faricimab patients were able to go 4 months between treatments, and approximately three-quarters could be treated every 3 months or longer. Two papers published in The Lancet highlight one-year results.